Compare NLOP & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NLOP | CCCC |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.4M | 185.1M |
| IPO Year | 2022 | 2020 |
| Metric | NLOP | CCCC |
|---|---|---|
| Price | $13.91 | $3.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $46.00 | $12.20 |
| AVG Volume (30 Days) | 316.9K | ★ 2.3M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 46.97% | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $118,915,000.00 | $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $12.76 | $1.09 |
| 52 Week High | $34.53 | $3.64 |
| Indicator | NLOP | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 31.73 | 72.92 |
| Support Level | $12.76 | $1.96 |
| Resistance Level | $20.22 | N/A |
| Average True Range (ATR) | 0.52 | 0.30 |
| MACD | 0.17 | 0.09 |
| Stochastic Oscillator | 68.74 | 96.28 |
Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.